This case report demonstrates the feasibility of using the SAPIEN 3 valve for valve-in-valve pulmonary valve implantation in a high-risk patient with severe biventricular heart failure.
Objective: Transcatheter valve-in-valve pulmonary valve implantation (ViV-TPVI) with SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA) is effective for treating insufficient prosthetic valves in right ventricular outflow tract diseases. SAPIEN 3 is primarily used to replace failed aortic valves; therefore, there is limited published data on the outcomes of its use for ViV-TPVI. In patients with severe heart failure, every procedure can lead to collapse during TPVI. This case report aims to describe the procedural strategy, perioperative management, and short-term outcomes of ViV-TPVI with SAPIEN 3 in a patient with biventricular heart failure, where careful preparation and prerisk assessment were critical to procedural success.
Shima et al. (Thu,) studied this question.